跳至主要内容

HLA B 27 Disease Association

CPT

81374

Synonyms
  • Ankylosing Spondylitis
  • B27 Disease Association
  • Disease Association Testing

Test Details

Methodology

Polymerase chain reaction (PCR)/sequence-specific oligonucleotide probes (SSOP)

This test is a class I antigen level test.

Result Turnaround Time

3 - 7 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

For more information, please view the literature below.

Human Leukocyte Antigen B27: Regulating the Immune Response

Use

Evaluate spondyloarthritis and other disorders associated with HLA-B27

Special Instructions

If you have questions, please telephone 800-533-1037 (HLA customer service) for assistance selecting the proper HLA test for the patient.

Limitations

Regarding whole blood specimens, an adequate test requires the presence of intact lymphocytes at the time of testing. Even taking appropriate precautions, an occasional specimen will not be satisfactory for testing. In such cases, fresh blood should be drawn for retesting.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

References

Braun WE, Zachary AA. The HLA histocompatibility system in autoimmune states. Clin Lab Med. 1988 Jun; 8(2):351-372. 3284701
Calin A, Fries JP. Striking prevalence of ankylosing spondylitis in “Healthy” w27 positive males and females. N Engl J Med. 1975 Oct 23; 293(17):835-839. 126380
Keat A. Reiter's syndrome and reactive arthritis in perspective. N Engl J Med. 1983 Dec 29; 309(26):1606-1615. 6358890
Khan MA, Khan MK. Diagnostic value of HLA-B27 testing in ankylosing spondylitis and Reiter's syndrome. Ann Intern Med. 1982 Jan; 96(1):70-76. 7053711
Lipsky PE, Taurog JD. The Second International Simmons Center Conference on HLA-B27-Related Disorders. Arthritis Rheum. 1991 Nov; 34(11):1476-1482. 1953825
Yu DT, Choo SY, Schaack T. Molecular mimicry in HLA-B27-related arthritis. Ann Intern Med. 1989 Oct 1; 111(7):581-591. 2672931

Custom Additional Information

HLA-B27 is strongly associated with ankylosing spondylitis (Marie-Strumpell disease). HLA-B27 shares homology with a Klebsiella protein and may imply a bacterial pathogenesis to ankylosing spondylitis. A patient with consistent clinical and radiographic findings who is B27-positive has a greater chance of having or developing ankylosing spondylitis than a negative patient. The antigen is not causative, however, and 10% of normal subjects are B27-positive. This test should not be considered a screening procedure for ankylosing spondylitis. The antigen is less strongly associated with Reiter syndrome and other arthritides than with ankylosing spondylitis. It has been linked with congenital deficiency of C4 and C2, and with adrenal hyperplasia.

Specimen Requirements

Specimen

Whole blood

Volume

Adult tube

Minimum Volume

0.5 mL (Note: This volume does not allow for repeat testing.)

Container

Lavender-top (EDTA) tube

Reference Range

The generic sequence coding for HLA-B27 is probed and reported as either P (positive) if it is present or N (negative) if it is absent.

Storage Instructions

Maintain blood specimen at room temperature.

Causes for Rejection

Hemolysis; clotted specimen; tube other than lavender-top (EDTA) tube

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
006924 HLA B 27 Disease Association 26043-0 006928 HLA-B27 26043-0
Order Code006924
Order Code NameHLA B 27 Disease Association
Order Loinc26043-0
Result Code006928
Result Code NameHLA-B27
UofM
Result LOINC26043-0